Palvella Therapeutics Announces Pipeline Update on QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ Rapamycin) for Serious, Rare Genetic Skin Diseases with No FDA-approved Therapies
21 févr. 2023 07h30 HE
|
Palvella Therapeutics
- Pivotal Phase 3 data for the treatment of Pachyonychia Congenita anticipated mid-2023 - - Phase 2 data for the treatment of Microcystic Lymphatic Malformations anticipated March 2023 - - Phase 2b...
Palvella Therapeutics Completes $45 Million Series C Financing
28 mai 2020 16h08 HE
|
Palvella Therapeutics
Investor Syndicate Comprised of Leading Biotech Investors Proceeds to Accelerate Pipeline of Rare Disease Therapies, Including Late-Stage Programs in Pachyonychia Congenita and Gorlin Syndrome ...
Palvella Therapeutics Completes Enrollment in Phase 2/3 Pivotal Study of PTX-022 for Treatment of Pachyonychia Congenita
06 mars 2020 07h00 HE
|
Palvella Therapeutics
Wayne, PA , March 06, 2020 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...
Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita
18 déc. 2018 08h00 HE
|
Palvella Therapeutics
Wayne, PA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...
Palvella Therapeutics Announces FDA Fast Track Designation for PTX-022 for Treatment of Pachyonychia Congenita
12 nov. 2018 08h00 HE
|
Palvella Therapeutics
Wayne, PA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...
Palvella Therapeutics to Present Update on PTX-022 at Pachyonychia Congenita Project Patient Support Meeting in London, UK
19 oct. 2018 08h00 HE
|
Palvella Therapeutics
Wayne, PA, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...
Palvella Therapeutics Appoints Rare Disease Senior Executive Elaine J. Heron, PhD to Board of Directors
05 sept. 2018 08h00 HE
|
Palvella Therapeutics
Wayne, PA, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and commercializing pathogenetically targeted therapies for...